Age-stratified risk of major adverse cardiovascular events with JAK inhibitors in rheumatoid arthritis: A nationwide cohort study.
Abstract
Background
The cardiovascular safety of Janus kinase inhibitors (JAKi) compared with biological disease-modifying antirheumatic drugs (bDMARDs) and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis (RA) remains debated. We aimed to evaluate the risk of major adverse cardiovascular events (MACE) among patients with RA initiating these therapies.
Methods
AND
Findings
We conducted a retrospective, population-based cohort study using the Taiwan National Health Insurance Research Database (2010-2022). We matched adults with incident RA into JAKi, bDMARD, and csDMARD cohorts. The primary outcome was incident MACE. We used inverse probability of treatment weighting (IPTW) and multivariable Cox proportional hazards models to estimate adjusted hazard ratios (aHRs). The weighted analytic cohort included 6856 patients (814 JAKi, 1613 bDMARD, and 4429 csDMARD users). Compared with csDMARDs, overall MACE risk was lower for JAKi (aHR 0.73, 95% CI 0.54-0.99) and bDMARDs (aHR 0.60, 95% CI 0.48-0.76). While the overall MACE risk did not differ significantly between JAKi and bDMARDs (aHR 1.22, 95% CI 0.87-1.72), JAKi initiation was associated with a higher MACE risk than bDMARDs among patients with at least one cardiovascular risk factor who were aged 50 years or older (aHR 1.80, 95% CI 1.13-2.89) and 65 years or older (aHR 4.45, 95% CI 2.30-8.63).
Conclusions
Initiating JAKi or bDMARDs lowers the overall risk of MACE compared with csDMARDs alone. However, JAKi therapy carries a significantly higher MACE risk than bDMARDs in older patients with existing cardiovascular risk factors, highlighting the need for age- and risk-stratified therapeutic selection.